STM2457, a bioavailable and highly selective METTL3 inhibitor, can significantly increase CD40+ expression, reduce the presence of AML cells from peripheral blood, act on crucial stem cell lines, and promote phenotypic reversal to prevent the development of AML. This evidence concerns the gene CD40 and acute myeloid leukemia.